论文部分内容阅读
目的探讨可溶性白细胞介素６受体（ｓＩＬ－６Ｒ）在肺癌免疫机制中的作用及临床意义。方法用双抗体夹心酶联免疫吸附试验检测２１例肺癌患者和２０例正常对照者的血清ｓＩＬ－６Ｒ水平。结果肺癌组患者血清ｓＩＬ－６Ｒ水平（７８．２±２２．１ｎｇ／ｍｌ）明显高于健康对照组（３６．０±１５．０ｎｇ／ｍｌ）（Ｐ＜０．０１）。肺癌Ⅰ～Ⅱ期者血清ｓＩＬ－６Ｒ水平（６５．６±１８．３ｎｇ／ｍｌ）明显低于Ⅲ～Ⅳ期者（９０．２±２６．６ｎｇ／ｍｌ）（Ｐ＜０．０１）。肺癌化疗后血清ｓＩＬ－６Ｒ水平较化疗前下降，但差异无显著性（Ｐ＞０．０５）。结论ｓＩＬ－６Ｒ参与肺癌的发生和发展。测定肺癌患者血清中可溶性白细胞介素６受体水平，对肺癌的病情监测有一定价值
Objective To investigate the role and clinical significance of soluble interleukin 6 receptor (sIL-6R) in the immune mechanism of lung cancer. Methods The levels of serum sIL-6R in 21 lung cancer patients and 20 normal controls were detected by double-antibody sandwich enzyme-linked immunosorbent assay. Results Serum sIL-6R levels in patients with lung cancer (78.2±22.1 ng/ml) were significantly higher than those in healthy controls (36.0±15.0 ng/ml) (P<0.01). The serum levels of sIL-6R in patients with stage I to II of lung cancer (65.6±18.3ng/ml) were significantly lower than those in stage III to IV (90.2±26.6ng/ml) (P<0.01). The level of serum sIL-6R after chemotherapy in lung cancer was lower than that before chemotherapy, but there was no significant difference (P>0.05). Conclusion sIL-6R is involved in the occurrence and development of lung cancer. To determine the levels of soluble interleukin 6 receptor in serum of lung cancer patients and have certain value in the monitoring of lung cancer